Copper in tumors and the use of copper-based compounds in cancer treatment

Autor(es)

Silva, Daniela Almeida da ^[1] ; De Luca, Anastasia ^[2] ; Squitti, Rosanna ^[3] ; Rongioletti, Mauro ^[4] ; Rossi, Luisa ^[5] ; Machado, Camila M. L. ^{[6, 7]} ; Cerchiaro, Giselle ^[1]

Afiliação do(s) autor(es)

^[1] Fed Univ ABC UFABC, Met Biochem & Oxidat Stress Lab, Ctr Nat Sci & Humanities, Ave Estados 5001, Bloco B, Santo Andre, SP - Brazil

^[2] Univ Roma Tor Vergata, Dept Biol, Fdn Umberto Veronesi, Via Ric Sci 1, I-00133 Rome - Italy

^[3] IRCCS Ist Ctr San Giovanni di Dio Fatebenefratell, Mol Markers Lab, Brescia - Italy

^[4] San Giovanni Calibita Fatebenefratelli Hosp, Div Res & Dev, Dept Lab Med, Rome - Italy

^[5] Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome - Italy

^[6] Univ Sao Paulo, Lab Invest Med Med Nucl LIM43, Dept Radiol, Hosp Clin, Fac Med, Rua Dr Ovideo Pires de Campos 872, Sao Paulo, SP - Brazil

^[7] Univ Sao Paulo, Ctr Translac Oncol CTO, Dept Radiol & Oncol, Hosp Clin, Fac Med, Ave Dr Arnaldo 451, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: Journal of Inorganic Biochemistry; v. 226, JAN 2022.
• Citações Web of Science: 0

Resumo

Copper homeostasis is strictly regulated by protein transporters and chaperones, to allow its correct distribution and avoid uncontrolled redox reactions. Several studies address copper as involved in cancer development and spreading (epithelial to mesenchymal transition, angiogenesis). However, being endogenous and displaying a tremendous potential to generate free radicals, copper is a perfect candidate, once opportunely complexed, to be used as a drug in cancer therapy with low adverse effects. Copper ions can be modulated by the organic counterpart, after complexed to their metalcore, either in redox potential or geometry and consequently reactivity. During the last four decades, many copper complexes were studied regarding their reactivity toward cancer cells, and many of them could be a drug choice for phase II and III in cancer therapy. Also, there is promising evidence of using 64Cu in nanoparticles as radiopharmaceuticals for both positron emission tomography (PET) imaging and treatment of hypoxic tumors. However, few compounds have gone beyond testing in animal models, and none of them got the status of a drug for cancer chemotherapy. The main challenge is their solubility in physiological buffers and their different and non-predictable mechanism of action. Moreover, it is difficult to rationalize a structure-based activity for drug design and delivery. In this review, we describe the role (AU)

• Processo FAPESP: 19/04799-0 - Estudo da ação do cobre em doenças neurodegenerativas
• Beneficiário: Giselle Cerchiaro
• Modalidade de apoio: Bolsas no Exterior - Pesquisa
• Processo FAPESP: 20/14175-0 - Estudo de mecanismo da ação anticancerígena de novos complexos de cobre utilizando produtos naturais como ligantes
• Beneficiário: Giselle Cerchiaro
• Modalidade de apoio: Auxílio à Pesquisa - Regular